GlassScriptPhysician profile
John Nicholas Cavuto
NPI 1366483208
$4,631.27
in general payments reported to CMS, 2019-2025
25 companies · $528 in 2025
The $528 reported for 2025 was more than what 93% of Adolescent Medicine (Pediatrics) providers received nationally (typical 2025 total: $99.31).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $311 · 2020: $1,768 · 2021: $552 · 2022: $585 · 2023: $431 · 2024: $456 · 2025: $528.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,415.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,415.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $1,895.05 | 2019-2025 | |
| Glaxosmithkline, LLC. | $358.31 | 2019-2025 | Bexsero, Pediarix, Rotarix |
| Cranial Technologies, INC | $322.78 | 2019-2025 | Doc Band |
| Merck Sharp & Dohme LLC | $310.13 | 2019-2025 | Gardasil 9, Vaxneuvance, Vaxelis |
| Supernus Pharmaceuticals, INC. | $283.89 | 2021-2024 | Qelbree |
| Sanofi Pasteur INC. | $195.63 | 2019-2025 | |
| Corium, LLC | $192.40 | 2022-2025 | Azstarys |
| Neos Therapeutics, LP | $187.32 | 2019-2024 | Cotempla Xr-Odt, Adzenys Xr-Odt |
| Takeda Pharmaceuticals U.S.A., INC. | $152.70 | 2019-2022 | |
| Genentech USA, INC. | $118.26 | 2019-2021 | |
| Ironshore Pharmaceuticals INC. | $87.53 | 2019-2024 | |
| Ars Pharmaceuticals Operations, INC. | $79.40 | 2025 | Neffy |
| Tris Pharma INC | $71.82 | 2020-2025 | Dyanavel Xr |
| Alk-Abello, INC | $52.09 | 2025 | Neffy |
| Sobi, INC | $48.92 | 2019-2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aytu Biopharma, INC. | $44.60 | 2023-2025 | Karbinal |
| Biogen, INC. | $43.29 | 2021 | |
| Vertical Pharmaceuticals, LLC | $39.78 | 2019-2024 | Relexxii |
| Collegium Pharmaceutical, INC. | $28.18 | 2025 | Jornay Pm |
| Abbvie INC. | $28.18 | 2022 | |
| Adlon Therapeutics L.P. | $25.67 | 2019-2020 | |
| Amgen INC. | $19.03 | 2024 | Actimmune |
| Seqirus USA INC | $17.45 | 2025 | Flucelvax |
| Astrazeneca Pharmaceuticals LP | $16.95 | 2024 | Flumist Quadrivalent |
| Kaleo, INC. | $11.91 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Cavuto listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.